Dr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES UNVEILS GROUNDBREAKING RESEARCH ON COGNITION AND SLEEP, EXTENDS COLLABORATION WITH UNIVERSITY OF OXFORD

Cognetivity Neurosciences Ltd. has released important validation results for the use of its Cognica technology in measuring the impact of changes in sleep patterns on brain health, as well as further collaboration with Oxford University to detect the earliest signs of impairment associated with diseases such as Alzheimer's.

Cognetivity's chief innovation officer, Dr. Seyed-Mahdi Khaligh-Razavi, will be presenting results on recent work on the impact of sleep on brain health at the 10th Congress of Asian Sleep Research (ASRS) on March 31 in Istanbul, Turkey. Normal sleep is essential for overall brain health and well-being, including cognition and memory formation. However, sleep disorders are highly prevalent and may affect 30 to 48 per cent of older adults. To date, evaluating cognitive function, both subjectively and objectively, can be cumbersome and costly, but tracking cognitive performance in sleep disorders can help identify the appropriate frequency and duration of treatment, as well as optimize proposed lifestyle changes to meet individual needs.

At the conference, Dr. Khaligh-Razavi will present results showing the application of Cognica in tracking cognitive performance in relation to sleep. For patients with sleep disorders, the impact of treatment on their cognition, as measured quantitatively by Cognetivity's Cognica technology, can be easily used to identify the optimal frequency and duration of treatment for each person. This then allows individuals to improve their brain health by improving their sleep patterns.

This can open up a huge market for Cognetivity, with the sleep technology devices market expected to grow from 15 billion in 2021 to over 67 billion in 2030, as well as growing interest in consumers in tracking sleep and measuring the impact on performance and health.

Cognetivity also announces the extension of its partnership with Oxford University on monitoring the cognition of individuals at risk of developing dementia. The purpose of the project is to detect the earliest signs of changes to allow the earliest possible intervention to preserve brain function and have the greatest positive impact of treatment. The study works with the Great Minds cohort, run by Dementia Platform U.K., a business and research consortium which includes Astrazeneca, GSK, Janssen and Cognetivity as partners.

Cognetivity's chief executive officer, Dr. Sina Habibi, commented, "We are always delighted to share results from our ongoing R&D [research and development] activities, especially when they open up markets as significant as managing sleep patterns, an area of growing concern for individuals and clinicians worldwide." He added, "When we add this to the expansion of our collaboration with such a fantastic academic partner as Oxford University, it shows our continued ability to deliver cutting edge research that demonstrates new use cases for our technology and its relevance and suitability for next-generation health care and consumer wellness."

Cognetivity also announces that, effective immediately, David Velisek has resigned as a director of the company in order to concentrate on other projects. Mr. Velisek has been a director of the company since Dec. 11, 2015, and in that time has provided significant value that has materially contributed to the strategic direction, growth and success of the company. The company extends its sincere gratitude to Mr. Velisek for his service and contributions he has made to the company and wishes him every success in his future endeavours.

The company also announces that it has entered into debt settlement agreements with certain creditors of the company to issue an aggregate of 816,555 common shares in the capital of the company at a deemed price of 32.5 cents per debt share to settle an aggregate of approximately $265,380 of outstanding debt; 658,892 of such common shares were issued to Dr. Thomas Sawyer, chief operating officer, chief financial officer, corporate secretary and a director of the company.

The issuance of the Sawyer shares to Dr. Sawyer constitutes a related party transaction, as this term is defined in Multilateral Instrument 61-101 -- Protection of Minority Securityholders in Special Transactions (MI 61-101). Pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, the company is exempt from obtaining a formal valuation and minority shareholder approval, as neither the fair market value of the amounts owed to Dr. Sawyer nor the Sawyer shares exceeds 25 per cent of the company's market capitalization.

No new insiders nor control persons were created as a result of the issuance of the debt settlement shares. The company did not file a material change report more than 21 days before the expected closing of the related party transaction as the details of the applicable debt settlement agreement were not finalized until closer to the closing date of the transaction, and the company wanted to close the transaction as soon as possible as part of broader efforts to reduce liabilities on the balance sheet.

The company also announces the issuance of an aggregate of 356,875 common shares to certain advisers, employees and consultants in accordance with the terms of their agreements.

All debt settlement shares and common shares issued to a certain adviser, employees and consultants are subject to a statutory hold period expiring on July 24, 2023, in accordance with applicable securities laws and the policies of the Canadian Securities Exchange.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's ICA uses artificial intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the United States, United Kingdom, Europe and the Middle East, with regulatory approval for other regions planned for 2023.

We seek Safe Harbor.